<DOC>
	<DOCNO>NCT01324583</DOCNO>
	<brief_summary>Primary Objective : - To assess tolerability global dose Secondary Objectives : - Safety - Pharmacokinetics - Efficacy</brief_summary>
	<brief_title>Dose Escalation Study With Cabazitaxel Combination With Daily Prednisolone Patients With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>The duration screen within 28 day , treatment 3 weeks/cycle follow-up 30 day last cabazitaxel administration .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Inclusion criterion : I 01 . Diagnosis histologically cytologically proven prostate adenocarcinoma , refractory hormone therapy ( receive prior castration orchiectomy and/or internal medicine , document progression disease relapse ) previously treat docetaxel . I 02 . Signed informed consent prior begin protocol specific procedure . I 03 . Patients PSA &gt; 20 ng/mL screening . Exclusion criterion : E 01 . Age &lt; 20 &gt; 74 E 02 . ECOG performance status ≥2 . E 03 . Prior surgery ≤4 week registration study . E 04 . Active secondary cancer include prior malignancy patient diseasefree ≤5 year ( However , adequately treat superficial basal cell skin cancer 4 week prior registration eligible study ) E 05 . Inadequate organ function include : Neutrophils &lt; 2.0 x 109/L Platelets &lt; 100 x 109/L Hemoglobin &lt; 9.0 g/dL ( transfusion prohibition within 14 day registration ) Creatinine &gt; 1.5 mg/dL . Total bilirubin &gt; 1.5 time upper normal limit institutional norm ALT/AST &gt; 1.5 time upper normal limit institutional norm E 06 . Previous treatment &lt; 225 mg/m2 cumulative dose Taxotere® ( docetaxel ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>73 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>